Stay updated with breaking news from Ben Yerxa. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Triangle Venture Day, hosted at Apella by Alexandria at the Alexandria Center for Advanced Technologies campus, proved to be one of promise of the Triangle’s growing innovation ecosystem, optimism for high-impact science, and enthusiasm for local collaboration.
Opus Genetics, a Research Triangle Park drug development startup focused on inherited diseases of the retina, has raised an additional $4.5 million in funding from investors.
Opus Genetics, a Durham-based company developing drugs to treat retinal diseases has raised an additional $4.5 million from investors. Here's how the CEO plans to invest the money.
RTP gene therapy startup Opus Genetics has acquired the rights to two pre-clinical product candidates to treat inherited retinal diseases from New Jersey biopharm company Iveric Bio.
Opus to advance preclinical development programs for BEST1- and RHO-related retinal diseases Opus Genetics, a patient-first, clinical-stage gene therapy company